Marbocare

Main information

  • Trade name:
  • Marbocare flavour 5mg, 20mg & 80mg Tablets for dogs and cats
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Marbocare flavour 5mg, 20mg & 80mg Tablets for dogs and cats
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Fluoroquinolones
  • Therapeutic area:
  • Cats Non Food, Dogs Non Food

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0470/001
  • Authorization date:
  • 26-06-2013
  • EU code:
  • UK/V/0470/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:September2013

AN:00538/2012

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Marbocareflavour5mgtabletsfordogsandcats(UKandIE)

MarbocareF5mgtabletsfordogsandcats(FR)

Odimar5mgtabletsfordogsandcats(BE,LU,NL)

MarbofloxacinWDT5mgflavouredtabletsforcatsanddogs(AT,DE)

MarbofloxacinoEmdoka5mgtabletsforcatsanddogs(ES)

MarbofloxacinaEmdoka5mgtabletsforcatsanddogs(PT)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:Marbofloxacin5.0mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet

Beigebrownspottedroundtabletswithascorelineononeside.

4. CLINICALPARTICULARS

4.1Targetspecies

DogsandCats

4.2Indicationsforuse,specifyingthetargetspecies

Marbofloxacinisindicatedinthetreatmentofthefollowinginfectionscausedby

susceptiblestrainsoforganisms(seesection5.1);

Dogs

Skinandsofttissueinfections(skinfoldpyoderma,impetigo,folliculitis,

furunculosis,cellulitis)

Urinarytractinfections(UTI)associatedornotwithprostatitisorepididymitis

Respiratorytractinfections

Issued:September2013

AN:00538/2012

Page2of6

Cats

Skinandsofttissueinfections(wounds,abscesses,phlegmons)

Upperrespiratorytractinfections

4.3Contraindications

Donotuseindogsagedlessthan12months,orlessthan18monthsforexceptionally

largebreedsofdogs,suchasGreatDanes,Briard,Bernese,BouvierandMastiffs,with

alongergrowthperiod.

Notrecommendedforuseincatsagedlessthan16weeks.

Donotuseinanimalswithknownhypersensitivitytomarbofloxacinorother

(fluoro)quinolonesortoanyoftheexcipients.

Donotuseincaseofconfirmedorsuspectedresistancetofluoroquinolones(cross

resistance).

4.4Specialwarningsforeachtargetspecies

AlowurinarypHcouldhaveaninhibitoryeffectontheactivityofmarbofloxacin.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Thefluoroquinoloneshavebeenshowntoinduceerosionofarticularcartilageinjuvenile

dogsandcareshouldbetakentodoseaccuratelyespeciallyinyounganimals.

However,atthetherapeuticrecommendeddosage,noseveresideeffectsaretobe

expectedindogsandcats.

Somefluoroquinolonesathighdosesmayhaveanepileptogenicpotential.Cautious

useisrecommendedindogsandcatsdiagnosedassufferingfromepilepsy.

Fluoroquinolonesshouldbereservedforthetreatmentofclinicalconditionswhichhave

respondedpoorly,orareexpectedtorespondpoorlytootherclassesofantimicrobials.

Wheneverpossible,useoffluoroquinolonesshouldbebasedonsusceptibilitytesting.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmayincreasethe

prevalenceofbacteriaresistanttothefluoroquinolonesandmaydecrease

effectivenessoftreatmentwithotherquinolonesduetothepotentialforcross-

resistance.

Issued:September2013

AN:00538/2012

Page3of6

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Peoplewithknownhypersensitivityto(fluoro)quinolonesshouldavoidusingthisproduct.

Incaseofaccidentalingestionseekmedicalattentionandshowproductlabeland/or

packageleaflettothedoctor.Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Mildsideeffectssuchasvomiting,softeningoffaeces,modificationofthirstortransient

increaseinactivitymayoccasionallyoccur.Thesesignsceasespontaneouslyafter

treatmentanddonotnecessitatecessationoftreatment.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryanimals(rats,rabbits)showednoteratogenicity,embryotoxicity

andmaternotoxicitywithmarbofloxacinattherapeuticdoses.

Thesafetyofmarbofloxacinhasnotbeenassessedinpregnantandlactatingcatsand

dogs.Useonlyaccordinglytothebenefit/riskassessmentbytheresponsible

veterinarianinpregnantandlactatinganimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Fluoroquinolonesareknowntointeractwithorallyadministeredcations(Aluminium,

Calcium,Magnesium,Iron).Insuchcases,thebioavailabilitymaybereduced.

Whenadministeredtogetherwiththeophylline,thehalf-lifeandthustheplasma

concentrationoftheophyllineincrease.Hence,incaseofconcurrentadministrationthe

doseoftheophyllineshouldbereduced.

4.9Amountstobeadministeredandadministrationroute

Fororaladministration.

Therecommendeddoserateis2mg/kg/dayinasingledailyadministration(seetable

below).

BodyWeight Tablets

1.3 –2.5kg 1

2.6 –5.0kg 2

Issued:September2013

AN:00538/2012

Page4of6

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

DOGS:

 Inskinandsofttissueinfections,treatmentdurationisatleast5days.Depending

onthecourseofthedisease,itmaybeextendedupto40days.

 Inurinarytractinfections,treatmentdurationisatleast10days.Dependingonthe

courseofthedisease,itmaybeextendedupto28days.

Inrespiratoryinfections,treatmentdurationisatleast7daysanddependingonthe

courseofthedisease,itmaybeextendedupto21days.

CATS:

 Forskinandsofttissueinfections(wounds,abscesses,phlegmons)treatment

durationis3to5days.

 Forupperrespiratoryinfectionstreatmentdurationis5days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Overdosagemaycauseacutesignsintheformofneurologicaldisorders,whichshould

betreatedsymptomatically.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse;

Fluoroquinolones;Marbofloxacin.

ATCvetcode:QJ01MA93

5.1Pharmacodynamicproperties

Marbofloxacinisasynthetic,bactericidalantimicrobial,belongingtothefluoroquinolone

groupwhichactsbyinhibitionofDNAgyrase.Itiseffectiveagainstawiderangeof

Grampositivebacteria(inparticularStaphylococci,Streptococci)andGramnegative

bacteria(Escherichiacoli,Salmonellatyphimurium,Citrobacterfreundii,Enterobacter

cloacae,Serratiamarcescens,Morganellamorganii,Proteusspp,Klebsiellaspp,

Shigellaspp,Pasteurellaspp,Haemophilusspp,Moraxellaspp,Pseudomonasspp,

Brucellacanis)aswellasMycoplasmaspp.

BacterialstrainswithaMIC≤1µg/mlaresusceptible,strainswithaMICof2µg/mlare

intermediatelysusceptibleandstrainswithaMIC≥4µg/mlareresistantto

marbofloxacin(CLSI,2004).MIC

90 valuesofmarbofloxacinforstrainsof

Staphylococcus(pseudo)intermedius,EscherichiacoliandPasteurellamultocida

Issued:September2013

AN:00538/2012

Page5of6

isolatedfromdiseasedcatsanddogsinGermanywere0.5µg/ml,0.5µg/mland0.06

µg/ml,respectively.

Resistancetofluoroquinolonesoccursmostlybychromosomalmutationwiththree

mechanisms:decreaseofthebacterialwallpermeability,expressionofeffluxpumpor

mutationofenzymesresponsibleformoleculebinding.

Marbofloxacinisnotactiveagainstanaerobes,yeastsorfungi.

5.2Pharmacokineticparticulars

Afteroraladministrationindogsandcatsattherecommendeddoseof2mg/kg,

marbofloxacinisreadilyabsorbedandreachesmaximalplasmaconcentrationsof1.5

µg/mlwithin2hours

Itsbioavailabilityiscloseto100%.

Itisweaklyboundtoplasmaproteins(lessthan10%),extensivelydistributedandin

mosttissues(liver,kidney,skin,lung,bladder,digestivetract)itachieveshigher

concentrationsthaninplasma.Marbofloxaciniseliminatedslowly(t½ß=14hindogs

and10hincats)predominantlyintheactiveforminurine(2/3)andfaeces(1/3).

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

Povidone(K90)

Silica,colloidalhydrated

Crospovidone(TypeA)

CastorOil,Hydrogenated

Dessicatedporkliverpowder

Driedyeast

Magnesiumstearate

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale;3years.

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

Issued:September2013

AN:00538/2012

Page6of6

6.5Natureandcompositionofimmediatepackaging

TheproductispackagedinAluminium-PVC/aluminium/polyamideblister

Boxcontaining1blisterof10tablets(10tablets)

Boxcontaining2blistersof10tablets(20tablets)

Boxcontaining10blistersof10tablets(100tablets)

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

EmdokaBvba

JohnLijsenstraat16

B-2321Hoogstraten

Belgium

8. MARKETINGAUTHORISATIONNUMBER

Vm34534/4003

9. DATEOFFIRSTAUTHORISATION

04September2013

10.DATEOFREVISIONOFTHETEXT

September2013

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable.

Approved:04/09/2013

13-12-2018

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Evaluation of the safety and efficacy of the organic acids lactic and acetic acids to reduce microbiological surface contamination on pork carcasses and pork cuts

Published on: Wed, 12 Dec 2018 Studies evaluating the safety and efficacy of lactic and acetic acids to reduce microbiological surface contamination on pork carcasses pre‐chill and pork meat cuts post‐chill were assessed. Lactic acid treatments consisted of 2–5% solutions at temperatures of up to 80°C applied to carcasses by spraying or up to 55°C applied on cuts by spraying or dipping. Acetic acid treatments consisted of 2–4% solutions at temperatures of up to 40°C applied on carcasses by spraying or o...

Europe - EFSA - European Food Safety Authority Publications

7-12-2018

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Re‐evaluation of propane‐1,2‐diol esters of fatty acids (E 477) as a food additive

Published on: Thu, 06 Dec 2018 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of propane‐1,2‐diol esters of fatty acids (E 477) when used as a food additive. The Scientific Committee on Food (SCF) in 1978 endorsed the acceptable daily intake (ADI) of 25 mg/kg body weight (bw) per day, expressed as propane‐1,2‐diol, established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) in 1974. No adverse effects were observed in short‐t...

Europe - EFSA - European Food Safety Authority Publications

4-12-2018

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylam

– Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochloroth...

FDA - U.S. Food and Drug Administration

28-11-2018

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity

Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).

Health Canada

21-11-2018

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall to the consumer level of select lots of Valsartan-containing products, including six lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), seven lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths), and two lots of Valsartan and Hydrochlorothiazide Tablets, USP 320mg/25mg strength. ...

FDA - U.S. Food and Drug Administration

17-10-2018

Pest categorisation of Stagonosporopsis andigena

Pest categorisation of Stagonosporopsis andigena

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The Panel on Plant Health performed a pest categorisation of Stagonosporopsis andigena, the causal agent of black blight of potato, for the EU. The pest is a well‐defined fungal species and reliable methods exist for its detection and identification. S. andigena is present in Bolivia and Peru. The pest is not known to occur in the EU and is listed in Annex IAI of Directive 2000/29/EC as Phoma andina, meaning its introduction into the EU is prohibited. The ma...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

12-7-2018

Minister Bruno Bruins bereikt akkoord over vergoeding Spinraza

Minister Bruno Bruins bereikt akkoord over vergoeding Spinraza

Minister Bruno Bruins (Medische Zorg) heeft  een akkoord bereikt met fabrikant Biogen. Hierdoor komt het middel Spinraza voor circa 80 jonge kinderen met de spierziekte Spinale Musculaire Atrofie (SMA) vanaf 1 augustus in het basispakket.  

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

1-8-2018

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Active substance: Meningococcal group A, C, W-135 and Y conjugate vaccine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5220 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2226/T/80

Europe -DG Health and Food Safety